Catalog No.
DVV00306
Expression system
Mammalian Cells
Species reactivity
SARS-CoV-2 (2019-nCoV)
Host species
Human
Isotype
IgG1, kappa
Clonality
Monoclonal
Target
Spike glycoprotein, S glycoprotein, E2, Peplomer protein, Spike protein S1, Spike protein S2, Spike protein S2', S, 2
Concentration
1.34 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P0DTC2
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
CB-6, JS-016, LY3832479, CAS: 2423948-94-9
Clone ID
Etesevimab
Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial, PMID: 33475701
Etesevimab, PMID: 34283469
Bamlanivimab, PMID: 33226744
Etesevimab and Bamlanivimab, PMID: 33630482
Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19, PMID: 34260849
A Narrative Review of the Clinical Practicalities of Bamlanivimab and Etesevimab Antibody Therapies for SARS-CoV-2, PMID: 34374951
An EUA for bamlanivimab and etesevimab for COVID-19, PMID: 33830966
Tolerability, Safety, Pharmacokinetics, and Immunogenicity of a Novel SARS-CoV-2 Neutralizing Antibody, Etesevimab, in Chinese Healthy Adults: a Randomized, Double-Blind, Placebo-Controlled, First-in-Human Phase 1 Study, PMID: 33972256
Bamlivimab + etesevimab therapy induces SARS-COV-2 immune escape mutations and secondary clinical deterioration in Covid-19 patients with B cell malignancies, PMID: 34352377
Efficacy of Bamlanivimab/Etesevimab and Casirivimab/Imdevimab in Preventing Progression to Severe COVID-19 and Role of Variants of Concern, PMID: 34435337
Emergence of Q493R mutation in SARS-CoV-2 spike protein during bamlanivimab/etesevimab treatment and resistance to viral clearance, PMID: 34437928
Neutralizing Antibody Therapeutics for COVID-19, PMID: 33916927
Development and application of therapeutic antibodies against COVID-19, PMID: 33907512
Initial experience of bamlanivimab monotherapy use in solid organ transplant recipients, PMID: 34081820
Monoclonal Antibody Therapy in a Vaccine Breakthrough SARS-CoV-2 Hospitalized Delta (B.1.617.2) Variant Case, PMID: 34271202
Editorial: Post-Exposure Prophylactic Neutralizing Monoclonal Antibodies to SARS-CoV-2 for Individuals at High Risk for COVID-19, PMID: 34393218
Perspectives on passive antibody therapy and peptide-based vaccines against emerging pathogens like SARS-CoV-2, PMID: 34422699
Post Acute Coronavirus (COVID-19) Syndrome, PMID: 34033370
Interventions in an Ambulatory Setting to Prevent Progression to Severe Disease in Patients With COVID-19: A Systematic Review, PMID: 34157890
Implementing a method for engineering multivalency to substantially enhance binding of clinical trial anti-SARS-CoV-2 antibodies to wildtype spike and variants of concern proteins, PMID: 34006961
An EUA for sotrovimab for treatment of COVID-19, PMID: 34181630
Update: Drug treatment options for coronavirus disease 2019 (COVID-19), PMID: 34433754
COVID antibody treatments show promise for preventing severe disease, PMID: 33712752
SARS-CoV-2 Variants: A Synopsis of In Vitro Efficacy Data of Convalescent Plasma, Currently Marketed Vaccines, and Monoclonal Antibodies, PMID: 34201767
Monoclonal Antibodies: Medical Uses for the Prevention and Treatment of Disease, PMID: 33861166
Prospective mapping of viral mutations that escape antibodies used to treat COVID-19, PMID: 33495308
An overview of the preclinical discovery and development of bamlanivimab for the treatment of novel coronavirus infection (COVID-19): reasons for limited clinical use and lessons for the future, PMID: 34304682
Emergence of SARS-COV-2 Spike Protein Escape Mutation Q493R after Treatment for COVID-19, PMID: 34314668
Monoclonal Antibodies for Early Treatment of COVID-19 in a World of Evolving SARS-CoV-2 Mutations and Variants, PMID: 34291118
Neutralising antibody escape of SARS-CoV-2 spike protein: Risk assessment for antibody-based Covid-19 therapeutics and vaccines, PMID: 33724631
The UPMC OPTIMISE-C19 (OPtimizing Treatment and Impact of Monoclonal antIbodieS through Evaluation for COVID-19) trial: a structured summary of a study protocol for an open-label, pragmatic, comparative effectiveness platform trial with response-adaptive randomization, PMID: 34034784
Effects of the glycosylation of the receptor binding domain (RBD dimer)-based Covid-19 vaccine (ZF2001) on its humoral immunogenicity and immunoreactivity. [DVV00306]
For research use only. Not for human or drug use.
